Amgen's Otezla notches another PhIII win; Califf earns advocacy groups' stamp of approval
Amgen’s blockbuster Otezla just racked up another Phase III win as it looks to continue expanding on its multibillion-dollar revenue stream.
The drug hit the primary endpoint in a trial researching its use in moderate to severe genital psoriasis, Amgen announced in the topline readout Wednesday afternoon. On top of that, all secondary endpoints were hit, demonstrating “meaningful and significant improvements,” the company said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.